The allure of healthcare has long captivated Big Tech giants. Over the past fifteen years or so, several prominent companies in the sector have ventured into the life sciences sector with ambitious projects, only to often find themselves retreating. The dynamic appears to be changing, particularly in drug discovery, thanks in part to burgeoning data…
NVIDIA and AWS collaborate to bring BioNeMo AI platform to the cloud
Chipmaker NVIDIA and cloud behemoth AWS have been partnering for years, and now the two companies are announcing that NVIDIA’s drug discovery generative AI platform, BioNeMo, is now available on AWS. Additionally, plans are underway for BioNeMo to be offered on AWS on NVIDIA DGX Cloud. The alliance was announced at the AWS re:Invent event.…
AI in drug development: Janssen exploring potential of AI in everything from target discovery to clinical trials
As enterprise AI adoption surges, the life science industry stands at a pivotal juncture. “We are truly at a tipping point,” remarked Najat Khan, chief data science officer at Janssen, during the 2023 Stanford Drug Discovery Symposium. “It’s amazing how quickly we’ve been able to make progress across the whole value chain in terms of…